Table 3 Impacts of the classification using IL-6 and IL-1β levels on overall survival and progression-free survival in patients with gemicitabine monotherapy for advanced pancreatic cancer

From: Serum levels of IL-6 and IL-1β can predict the efficacy of gemcitabine in patients with advanced pancreatic cancer

Overall survival
IL-6/IL-1 β classification N Median OS (95%CI) (days) HR (95% CI) P -value
IL-6Low/IL-1βLow 25 306 (228–355) 1 Ref.
IL-6Low/IL-1βHigh 5 246 (97–346) 1.48 (0.43–3.97) 0.497
IL-6High/IL-1βLow 15 140 (83–334) 1.90 (0.94–3.72) 0.074
IL-6High/IL-1βHigh 15 79 (61–134) 4.06 (1.96–8.18) <0.001
  1. Abbreviations: CI=confidence interval; HR=hazard ratio; IL=interleukin; OS=overall survival; PFS=progression-free survival.
Progression-free survival     
IL-6/IL-1 β classification N Median PFS (95%CI) (days) HR (95% CI) P -value
IL-6Low/IL-1βLow 25 158 (96–187) 1 ref
IL-6Low/IL-1βHigh 5 96 (42–229) 1.68 (0.56–4.11) 0.323
IL-6High/IL-1βLow 15 48 (23–92) 2.24 (1.14–4.29) 0.021
IL-6High/IL-1βHigh 15 46 (19–61) 4.26 (2.08–8.55) <0.001
  1. Abbreviations: CI=confidence interval; HR=hazard ratio; IL=interleukin; OS=overall survival; PFS=progression-free survival.